Drug interactions between Aliqopa and Stamaril
|Stamaril (yellow fever vaccine)|
Interactions between your drugs
yellow fever vaccine copanlisib
Applies to: Stamaril (yellow fever vaccine) and Aliqopa (copanlisib)
If you are currently being treated or have recently been treated with copanlisib, you should let your doctor know before receiving yellow fever vaccine. Depending on the dose and length of time you have been on copanlisib, you may be at risk for developing an infection from the vaccine or have a reduced response to the vaccine. In some situations, your doctor may want to delay vaccination to give your body time to recover from the effects of copanlisib therapy. Conversely, if you have recently been vaccinated with yellow fever vaccine, your doctor may choose to postpone treatment with copanlisib for a few weeks. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
Applies to: Aliqopa (copanlisib)
Grapefruit juice can increase the blood levels of copanlisib. This may increase side effects such as nausea, vomiting, diarrhea, mouth sores, high blood sugar, high blood pressure, lung or breathing problems, severe skin reactions, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should avoid the consumption of grapefruit and grapefruit juice during treatment with copanlisib. Talk to your doctor or pharmacist if you have questions on this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.